Jim Simons Renaissance Technologies
Jim Simons is the founder of Renaissance Technologies, one of the most successful quantitative hedge funds in the world. Before his career in finance, he served as a mathematics professor and made significant contributions to differential geometry. Simons applied his analytical expertise to develop sophisticated, algorithm-driven trading strategies, earning consistently high returns for investors.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Apple
AAPL
|
+$839M |
| 2 |
Amazon
AMZN
|
+$810M |
| 3 |
Tesla
TSLA
|
+$644M |
| 4 |
TSMC
TSM
|
+$546M |
| 5 |
Johnson & Johnson
JNJ
|
+$389M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Microsoft
MSFT
|
+$891M |
| 2 |
Home Depot
HD
|
+$441M |
| 3 |
JPMorgan Chase
JPM
|
+$335M |
| 4 |
NVO
Novo Nordisk
NVO
|
+$317M |
| 5 |
ASML
ASML
|
+$315M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 20.84% |
| 2 | Technology | 15.57% |
| 3 | Consumer Discretionary | 11.88% |
| 4 | Consumer Staples | 10.09% |
| 5 | Financials | 9.84% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
3326
Avalon Holdings
AWX
$10.3M
| $243K | ﹤0.01% |
88,310
-10,000
| -10% | -$26.9K |
|
|
APLT
3327
DELISTED
Applied Therapeutics
APLT
| $242K | ﹤0.01% |
317,978
-16,311
| -5% | -$12.9K |
|
3328
Sutro Biopharma
STRO
$354M
| $242K | ﹤0.01% |
2,990
-18,600
| -86% | -$1.29M |
|
3329
Verastem
VSTM
$587M
| $242K | ﹤0.01% |
50,082
-13,616
| -21% | -$66.8K |
|
|
GHSI
3330
DELISTED
Guardion Health Sciences, Inc. Common Stock
GHSI
| $242K | ﹤0.01% |
33,415
-1,064
| -3% | -$8.52K |
|
|
ONCT
3331
DELISTED
Oncternal Therapeutics, Inc. Common Stock
ONCT
| $242K | ﹤0.01% |
12,090
-36,900
| -75% | -$735K |
|
|
HARP
3332
DELISTED
Harpoon Therapeutics, Inc. Common Stock
HARP
| $242K | ﹤0.01% |
33,297
-14,807
| -31% | -$125K |
|
3333
Business First Bancshares
BFST
$1.05B
| $241K | ﹤0.01% |
10,900
-7,283
| -40% | -$167K |
|
3334
Cousins Properties
CUZ
$4.92B
| $240K | ﹤0.01% |
9,500
-359,831
| -97% | -$8.78M |
|
3335
KraneShares Bosera MSCI China A 50 Connect Index ETF
KBA
$147M
| $240K | ﹤0.01% |
+9,400
| New | +$274K |
|
|
SWKH
3336
DELISTED
SWK Holdings
SWKH
| $240K | ﹤0.01% |
17,163
-379
| -2% | -$5.58K |
|
|
PTRS
3337
DELISTED
Partners Bancorp Common Stock
PTRS
| $240K | ﹤0.01% |
27,100
+600
| +2% | +$5.32K |
|
3338
IBEX
IBEX
$477M
| $239K | ﹤0.01% |
+9,600
| New | +$217K |
|
3339
Invesco S&P SmallCap 600 Revenue ETF
RWJ
$2.11B
| $239K | ﹤0.01% |
6,600
-9,600
| -59% | -$349K |
|
|
AMOV
3340
DELISTED
America Movil SAB de CV
AMOV
| $239K | ﹤0.01% |
13,253
-1,000
| -7% | -$18.3K |
|
3341
Broadway Financial
BYFC
$114M
| $238K | ﹤0.01% |
29,412
-9,477
| -24% | -$77.5K |
|
3342
Urban One Class A
UONE
$23.9M
| $238K | ﹤0.01% |
5,230
-3,339
| -39% | -$180K |
|
3343
OppFi
OPFI
$619M
| $236K | ﹤0.01% |
115,100
+100
| +0.1% | +$225 |
|
3344
Energy Services of America
ESOA
$237M
| $235K | ﹤0.01% |
91,300
+35,000
| +62% | +$96.3K |
|
|
SOHO
3345
DELISTED
Sotherly Hotels
SOHO
| $235K | ﹤0.01% |
129,914
-63,100
| -33% | -$126K |
|
|
AMTI
3346
DELISTED
Applied Molecular Transport Inc. Common Stock
AMTI
| $235K | ﹤0.01% |
560,700
-118,600
| -17% | -$119K |
|
3347
Eltek
ELTK
$57.9M
| $234K | ﹤0.01% |
56,823
-16,892
| -23% | -$65.8K |
|
|
ARAV
3348
DELISTED
Aravive, Inc. Common Stock
ARAV
| $234K | ﹤0.01% |
177,513
-192,316
| -52% | -$246K |
|
3349
Skillful Craftsman
EDTK
$14.3M
| $233K | ﹤0.01% |
161,900
-8,400
| -5% | -$8.92K |
|
3350
Lisata Therapeutics
LSTA
$9.64M
| $233K | ﹤0.01% |
92,122
-8,800
| -9% | -$32.3K |
|
Similar funds
Jim Simons's Q4 2022 Portfolio in Review
As of Q4 2022, Jim Simons held 4,601 positions worth $73.1B, up 3.4% from $70.7B the previous quarter. Its ten largest holdings account for 11% of the portfolio.
Jim Simons's Q4 2022 filing shows 626 new, 1,390 increased, 2,018 reduced and 524 closed positions. Its largest new stake was Johnson & Johnson: 2,254,125 shares worth $398M. The largest sale was Microsoft, an estimated $891M.
By sector, the portfolio is most concentrated in Healthcare at 21% of assets, up from 19% a quarter earlier, followed by Technology and Consumer Discretionary.
- Jim Simons's largest Q4 2022 buy was Johnson & Johnson: 2,254,125 shares worth $398M.
- Jim Simons added most to Apple in Q4 2022, an estimated $839M increase.
- Jim Simons's biggest Q4 2022 reduction was Novo Nordisk, cutting an estimated $317M.
- Jim Simons fully exited Microsoft in Q4 2022, selling an estimated $891M.
- Jim Simons's ten largest holdings make up 11% of its $73.1B portfolio in Q4 2022.
- Jim Simons opened 626 new positions and closed 524 in Q4 2022.
- Jim Simons's portfolio value rose 3.4% quarter-over-quarter to $73.1B.
Based on Renaissance Technologies's 13F filing for Q4 2022, filed 13 Feb 2023.